Clinical study of adefovir compared with entecavir in the treatment of chronic hepatitis B

Objective To evaluate the clinical efficacy and safety of adefovir and entecavir in the treatment of chronic hepatitis B( CHB).Methods Eighty- six patients with CHB were recruited from 2012 to2013 in our hospital and randomly divided into adefovir group( n = 41)and entecavir group( n = 45). Patients in the adefovir group and entecavir group were given adefovir 0. 5 mg · d- 1,po and entecavir 10mg·d- 1,po,respectively. The treatment lasted for 12 months. The hepatitis B virus( HBV) DNA,HBV negative rate and adverse drug reactions in two groups were compared before and after treatment. Results After 12 months treatment,the HBV DNA were significantly decreased in both groups [( 4. 21 ± 0. 71) vs( 4. 01 ± 0. 68) log10 copies · m L- 1]with statistical difference( P 0. 05),but no statistical difference in HBV negative rate and ALT normal rate was found between the two groups( P 0. 05). Conclusion Significant clinical efficacy of both adefovir and entecavir was found in the treatment of chronic hepatitis B,with less adverse drug reactions.